Safety, Efficacy, and Patient‐Reported Outcomes From a Phase 2 Randomized Trial of Pozelimab and Cemdisiran Combination in Patients With Paroxysmal Nocturnal Hemoglobinuria

Documenti analoghi

• Clinical Profile, Humanistic and Economic Burden of Paroxysmal Nocturnal Hemoglobinuria in Patients Treated With C5 Inhibitors
  di: Shreyans Gandhi, et al.
  Pubblicazione: (2026)
• Paroxysmal Nocturnal Hemoglobinuria in Pregnancy Treated With Pegcetacoplan: Case Report and Pharmacokinetic Analysis
  di: Benjamin Chin‐Yee, et al.
  Pubblicazione: (2025)
• Successful Birth After First‐Trimester Ravulizumab Exposure in a Patient With Paroxysmal Nocturnal Hemoglobinuria: A Case Report
  di: Tatsuki Morioka, et al.
  Pubblicazione: (2025)
• EPYSQLI (SB12; Biosimilar to Reference Eculizumab) in Asian and Non‐Asian Patients With Paroxysmal Nocturnal Hemoglobinuria: Subgroup Analysis of a Global Phase III Randomized Controlled Trial
  di: Jun Ho Jang, et al.
  Pubblicazione: (2025)
• Effectiveness of Iptacopan Versus C5 Inhibitors in Complement Inhibitor‐Naive Patients With Paroxysmal Nocturnal Haemoglobinuria
  di: Matthew Holt, et al.
  Pubblicazione: (2025)